Avery Therapeutics has an exciting regenerative medicine program that centers around engineering tissues for therapeutic purposes. Our lead product is MyCardia™, an engineered cardiac tissue for treatment of heart failure of ischemic etiology. Avery has demonstrated optimal in vivo outcomes including improvements in all clinically relevant functional and quality of life parameters. Avery’s competitive advantage stems from the unique patented cellular formulation and attention to both scalability and human factors in design.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):